The original disclosure in Japanese was released on November 5, 2014 at 16:00 (GMT+9)

Consolidated Financial Statements for the Second Quarter Ended September 30, 2014 FY2015 (April 1, 2014 - March 31, 2015) [UNAUDITED]

Company name: Takara Holdings Inc.
Stock exchange listings: Tokyo Stock Exchange (1st section)
Code number: 2531
URL: http://www.takara.co.jp/
Company representative: Toshio Kakimoto, President
Contact: Takuya Kakemi, General Manager of Financial & Investor Relations Dept.
TEL : (075)241-5124

Quarterly statement filing date (as planned): November 11, 2014

Notes:
1. The accompanying financial statements have been prepared in accordance with accounting principles and practices generally accepted in Japan.
2. Amounts are rounded down to the nearest million yen.

1. Results for the six months ended September 30, 2014 (April 1, 2014 – September 30, 2014)

(1) Operating results

Note: Percentages indicated changes from the same period of the previous fiscal year.

	Six months ended September 30, 2014		Six months ended September 30, 2013	
	(Millions of yen)	(%)	(Millions of yen)	(%)
Net sales	101,130	3.7	97,561	1.9
Operating income	3,275	36.8	2,395	(17.4)
Ordinary income	3,429	33.7	2,564	(10.8)
Net income	1,828	(72.3)	6,609	-
Net income per share (Yen)	9.09		32.58	
Fully diluted net income per share (Yen)	-		32.58	
Note: Comprehensive income	1,196	(93.2)	17,559	-

(2) Financial position

	As of September 30, 2014	As of March 31, 2014
	(Millions of yen)	(Millions of yen)
Total assets	246,530	238,577
Net assets	145,761	146,422
Equity ratio (%)	49.1	50.9
(Reference) Equity	120,936	121,431

2. Dividends

	Dividend per share (Yen)		
	Year ended March 31, 2014	Year ending March 31, 2015	Year ending March 31, 2015 (Forecast)
First quarter end	-	-	
Second quarter end	-	-	
Third quarter end	-		-
Year end	11.00		9.00
Annual	11.00		9.00

Notes: Correction of dividend forecast from the most recent dividend forecast : No
The annual dividend for the year ended March 31, 2014 comprises an ordinary dividend of ¥9.00 and a special dividend of ¥2.00.

3. Forecast for the year ending March 31, 2015 (April 1, 2014 – March 31, 2015)

Note: Percentages indicated changes from the same period of the previous fiscal year.

	Year ending March 31, 2015	
	(Millions of yen)	(%)
Net sales	218,000	4.0
Operating income	9,800	3.3
Ordinary income	10,000	0.9
Net income	5,300	(48.4)
Net income per share (Yen)	26.34	

Note: Correction of financial forecast from the most recent financial forecast : No

4. Others

(1) Material changes in subsidiaries during this period
(Changes in scope of consolidations resulting from change in specific subsidiaries) : No

(2) Applying of specific accounting treatments of the quarterly consolidated financial statements : No

(3) Changes in accounting policies, changes in accounting estimates, and retrospective restatement
1) Changes based on revisions of accounting standard : Yes
2) Changes other than ones based on revisions of accounting standard : Yes
3) Changes in accounting estimates : Yes
4) Restatement : No

(4) Number of outstanding shares (common stock)
1) Number of outstanding shares at year end (Treasury stocks are included)
As of September 30, 2014 : 217,699,743
As of March 31, 2014 : 217,699,743
2) Number of treasury stocks at year end
As of September 30, 2014 : 16,473,370
As of March 31, 2014 : 16,466,424
3) Average number of outstanding shares
Six months ended September 30, 2014 : 201,228,886
Six months ended September 30, 2013 : 202,857,741

Contents of the attached document

1. Qualitative Information for the Six Months Ended September 30, 2014 ---------- 2
(1) Consolidated Financial Results ---------- 2
(2) Consolidated Financial Position ---------- 3
(3) Qualitative Information Regarding Consolidated Forecasts ---------- 4
2 Summary Information (Notes) ---------- 4
Change in Accounting Policies and Changes and Retrospective Restatement of Accounting Estimates---- 4
3. Consolidated Quarterly Financial Statements ---------- 6
(1) Consolidated Quarterly Balance Sheets ---------- 6
(2) Consolidated Quarterly Statements of Income and Consolidated Quarterly Statements of Comprehensive Income ---------- 8
Consolidated Quarterly Statements of Income
(For the Six Months Ended September 30, 2014 and 2013) ---------- 8
Consolidated Quarterly Statements of Comprehensive Income
(For the Six Months Ended September 30, 2014 and 2013) ---------- 9
(3) Consolidated Quarterly Statements of Cash Flows ---------- 10
(4) Notes on Consolidated Quarterly Financial Statements ---------- 11
(Notes on Premise of Going Concern) ---------- 11
(Notes on Material Changes in Shareholders' Equity) ---------- 11
(Segment Information) ---------- 11

○ Supplement for the Consolidated Quarterly Financial Statements

1. Qualitative Information for the Six Months Ended September 30, 2014

(1) Consolidated Financial Results

In the six months ended September 30, 2014, the Japanese economy experienced a slow recovery from the downturn following the increase in the rate of the consumption tax, partly as a result of unseasonable weather during the summer. In addition, the depreciation in the value of the yen, which had appeared to have settled down slightly, rapidly picked up speed going into September, and the prices of imported raw materials are predicted to rise. There are also concerns about a slump in consumer confidence with the increase in the price of consumer goods which has accompanied the increase in the rate of the consumption tax exceeding growth in real wages. Meanwhile, the uncertainty outside Japan persisted as economic growth in Europe and emerging countries clouded over slightly, and there were also some concerns about the impact of so-called geo-political risk while the economy in the United States remained firm.

In this environment, we endeavored to further improve corporate value in accordance with the three-year Takara Group Medium-Term Management Plan FY2017 under which our basic policy is that "To achieve the Takara Group Vision 2020 (our long-term vision), we will improve domestic business profitability and expand our overseas business, while at the same time building a well-balanced business structure that can hold up well to business environment changes by accelerating the growth of our Biomedical business."

In the domestic alcoholic beverages business, the Group focused its resources on developing original new products and cultivating brands in response to diversifying customer preferences. In the seasonings and raw alcohol business, the Group made concerted efforts to increase sales by proposing differentiated products that meet customer needs.

In the overseas alcoholic beverages business and Japanese food wholesale business in overseas markets, the Group worked to accelerate business expansion by spreading Japanese food culture across the globe

In the Biomedical business, management resources were focused on three areas – the Bioindustry business, the Gene Therapy business, and the AgriBio business – in pursuit of improved performance.

In the six months ended September 30, 2014, net sales were up 3.7% year on year to ¥101,130 million due to the inclusion of sales from subsidiaries that were newly consolidated during the previous fiscal year and an increase in sales at overseas subsidiaries due to the depreciation in the value of the yen among other factors. Gross profit also rose 4.5% year on year to ¥38,627 million in tandem with the increase in net sales.

Selling, general and administrative (SG&A) expenses were up 2.3% year on year to ¥35,351 million, successfully held down relative to the increase in gross profit, as personnel and other expenses outside Japan rose due to the new consolidation of subsidiaries and the depreciation in the value of the yen although advertising and promotion expenses declined. Consequently, operating income rose 36.8% year on year to ¥3,275 million. Non-operating income and expenses was roughly flat year on year although the foreign exchange gains of the same period in the previous fiscal year turned to foreign exchange losses and the stock issuance expenses recorded in the previous corresponding period was not recorded in the period under review. Thus, ordinary income also rose 33.7% to ¥3,429 million year on year.

In regard to extraordinary income and loss, extraordinary income fell considerably year on year as the gain on sales of subsidiaries and affiliates' stocks due to the sale of a portion of the stock held in Takara Bio Inc. recorded in the corresponding period of the previous fiscal year was not recorded in the period under review. As a result, income before income taxes and minority interests declined considerably by 71.8% year on year to ¥3,343 million, and net income also dropped 72.3% compared with the six months ended September 2013 to ¥1,828 million.

Results by business segment were as follows.

[Takara Shuzo Group]

In the six months ended September 2014, overall sales of mainstay shochu products declined considerably with sluggish sales of all products, particularly *ko*-type shochu. While sales of *Takara Shochu High Ball* were robust, sales of light-alcohol refreshers overall declined, partly in reaction to new products launched in the previous fiscal year. Meanwhile, sales of sake products increased, including the ever-popular sparkling sake *Sho-Chiku-Bai Shirakabe-gura Mio*, partly helped by the new *Sho-Chiku-Bai Ten with 70% reduced sugar* that was launched in September 2014. Nevertheless, the decline in shochu sales weighed heavily, and overall sales of alcoholic beverages declined as a result.

On the other hand, sales in Japanese food wholesale business in overseas markets rose substantially with the inclusion of sales at TAZAKI FOODS LTD. (UK) and COMINPORT DISTORIBUCIÓN S.L. (Spain), which were consolidated during the previous fiscal year. Therefore, total net sales for the Takara Shuzo Group overall increased 3.3% year on year to ¥88,515 million

Cost of sales was up 2.9% year on year to ¥56,846 million. However, the rate of increase was small relative to the growth in net sales despite increases in the cost of raw materials due to the depreciation in the value of the yen because of ongoing cost cutting initiatives and a decline in the cost of sales ratio due to changes in the product mix. Gross profit was also up 3.9% to ¥31,668 million. SG&A expenses only increased 1.6% year on year to ¥29,474 million because advertising and promotion expenses at Takara Shuzo Co., Ltd. fell despite the increases in personnel and other expenses at subsidiaries outside Japan. Accordingly, the Takara Shuzo Group recorded operating income up

49.9% year on year to ¥2,194 million for the six months ended September 2014.

[Takara Bio Group]

Net sales increased 6.8% to ¥10,971 million as sales of the mainstay research reagents exceeded those of the same period of the previous fiscal year, due in part to the effect of the depreciation in the value of the yen. Cost of sales was up 5.2% year on year to ¥4,916 million. Consequently, gross profit increased 8.1% to ¥6,054 million. Higher personnel expenses and other factors led to an increase of 5.4% in SG&A expenses to ¥5,429 million. Consequently, the Takara Bio Group recorded operating income up 37.6% to ¥625 million compared with the six months ended September 2013.

[Takara Healthcare]

Net sales for the six months ended September 2014 increased by 20.1% year on year to ¥810 million due to strong sales of the mainstay fucoidan-related products and isosamidin-related products in addition to sales growth for OEM cosmetics. Gross profit increased in conjunction with net sales, offsetting an increase in SG&A expenses including advertising expenses. Takara Healthcare recorded an operating profit of ¥30 million for the six months ended September 2014, an improvement of ¥35 million compared with the six months ended September 2013 when it recorded an operating loss of ¥4 million.

[Other]

Net sales of business segments other than the reported segments decreased 4.1% year on year to ¥3,336 million, and operating income was down 72.7% to ¥28 million due to increases in the cost of sales ratio and SG&A expenses.

Breakdown of sales results by product category

Segment	Equivalent Period of Previous Fiscal Year (From April 1, 2013, to September 30, 2013)	Period under Review (from April 1, 2014, to September 30, 2014)	YoY Comparison
Product category	Amount (Millions of yen)	Amount (Millions of yen)	(%)
Takara Shuzo Group			
Shochu	33,128	31,090	93.8
Sake	8,368	9,168	109.6
Light-alcohol refreshers	14,467	13,375	92.5
Other alcoholic beverages	5,986	6,335	105.8
Alcoholic beverages total	61,950	59,970	96.8
Hon Mirin	6,811	6,465	94.9
Other seasonings	3,940	4,107	104.2
Seasonings total	10,751	10,573	98.3
Raw alcohol, etc.	3,184	3,171	99.6
Transportation	5,692	5,645	99.2
Japanese food wholesale business in overseas markets	3,345	8,390	250.8
Other	785	764	97.3
Total	85,712	88,515	103.3
Takara Bio Group	10,277	10,971	106.8
Takara Healthcare	674	810	120.1
Other	3,477	3,336	95.9
Sales not allocated to business segments and intersegment transactions	(2,579)	(2,502)	-
Total	**97,561**	**101,130**	**103.7**

Notes: Amounts include alcohol tax but do not include consumption tax.

(2) Consolidated Financial Position

Total assets stood at ¥246,530 million as of September 30, 2014, up ¥7,953 million from March 31, 2014, the end of the previous fiscal year. This was due to a ¥3,782 million increase in current assets from the end of the previous fiscal year to ¥154,334 million resulting from factors including an increase in securities for the management of surplus funds and increase in inventories despite a decrease in cash and deposits and notes and accounts receivable-trade. Noncurrent assets increased by ¥4,171 million to ¥92,196 million due to such factors as an increase in property, plant and equipment

due to capital expenditure and an increase in investment securities due to a rise in the market prices of listed stocks and other items.

Total liabilities amounted to ¥100,769 million as of September 30, 2014, up ¥8,614 million from March 31, 2014. The main changes were an increase in long-term loans payable, an increase in other, current liabilities due to accrued payments relating to the acquisition of property, plant and equipment, and a decrease in income taxes payable.

Net assets stood at ¥145,761 million as of September 30, 2014, down ¥661 million from March 31, 2014 due to a fall in accumulated other comprehensive income resulting from a decline in foreign currency translation adjustment despite an increase in valuation difference on available-for-sale securities.

Net cash used in operating activities in the six months ended September 30, 2014 was ¥1,306 million, a decrease of ¥580 million in cash used in operating activities in the six months ended September 30, 2013. Major factors increasing cash included income before income taxes and minority interests and depreciation and amortization in addition to a decrease in notes and accounts receivables-trade. However, these were outweighed by factors reducing cash such as an increase in inventories and outflow of income taxes paid based on taxable income from the previous fiscal year and other payments.

Net cash used in investing activities in the six months ended September 30, 2014 amounted to ¥4,873 million, an increase of ¥2,883 million in cash used in investing activities in the six months ended September 30, 2013. Outflows came in the form of payments for the purchase of investment securities and the purchase of property, plant and equipment and intangible assets.

Net cash provided by financing activities was ¥7,339 million, up ¥3,050 million year on year due to proceeds from long-term loans payable despite cash dividends paid.

As a result, cash and cash equivalents as of September 30, 2014 stood at ¥35,296 million, up ¥687 million from the previous fiscal year-end.

(3) Qualitative Information Regarding Consolidated Forecasts

Full-year consolidated net sales are expected to be in line with initial forecasts overall, so forecasts for the Group overall are unchanged. This is because although the Takara Shuzo Group's net sales outside Japan are likely to exceed initial forecasts due to the strong performance of the Japanese food wholesale business in overseas markets as well as the effect of the depreciation in the value of the yen, there are concerns over a decline in sales in Japan due to the delayed recovery in consumption trends.

While consolidated income figures slightly exceeded the initial forecasts for the six months ended September 30, 2014, the business environment for the Takara Shuzo Group's domestic alcoholic beverages business, which experiences peak demand from now through to the end of the year, and the recovery in personal consumption remain uncertain although the Japanese food wholesale business in overseas markets will continue to perform well. Initial forecasts of operating income for the Takara Bio Group are unchanged while forecast ordinary income has been revised upward slightly. However, the initial full-year forecasts for consolidated operating income, ordinary income and net income for the Group as a whole are unchanged.

2. Summary Information (Notes)

Change in Accounting Policy and Retrospective Restatement of Accounting Estimates

(Change in Accounting Policy)

(Application of Accounting Standard for Retirement Benefits)

The Company adopted the provisions in the main text of paragraph 35 of the Accounting Standard for Retirement Benefits (Accounting Standards Board of Japan ("ASBJ") Statement No. 26, May 17, 2012) and the main text of paragraph 67 of the Application Guidance on Accounting Standard for Retirement Benefits (ASBJ Guidance No. 25, May 17, 2012) from the first quarter of this fiscal year, revising the method of calculating retirement benefit obligations and service expenses, modifying the method of attributing expected benefit to periods from the straight-line basis to the benefit formula basis as well as changing the discount rate from one based on the average remaining service years of its employees to a single weighted average discount rate reflecting the expected timing and amount of benefit payments.

In accordance with the transitional measures provided for in paragraph 37 of the Accounting Standard for Retirement Benefits for the application of the Accounting Standard for Retirement Benefits and its Guidance, the effect of the change in the method of calculation of retirement benefit obligations and service costs has been added to or deducted from retained earnings as of the beginning of the first half of this fiscal year (the half ended September 30, 2014).

As a result, at the beginning of the first half of this fiscal year, net defined benefit liabilities fell ¥313 million while other in investments and other assets increased by ¥359 million, retained earnings increased by ¥414 million and minority interests increased by ¥16 million. The impact on consolidated operating income, ordinary income and income before income taxes and minority interests in the six months ended September 30, 2014 was immaterial.

(Change in Accounting Policy that is Difficult to Distinguish from Change in Accounting Estimates)

(Change in Method of Depreciation for Property, Plant and Equipment)

Consolidated subsidiary Takara Bio Inc. previously applied declining balance depreciation to property, plant and equipment but switched to straight-line depreciation from the three months ended June 30, 2014.

Takara Bio reconsidered its method of depreciation and determined that this change from declining balance to straight-line depreciation is reasonable in view of the fact that the stable utilization of property, plant and equipment in research and development and production activities is anticipated because it has been 12 years since the company was established and facilities that include the Center for Gene and Cell Processing will be in operation from this fiscal year.

The impact of this change on consolidated operating income, ordinary income and income before income taxes and minority interests in the six months ended September 30, 2014 is an increase of ¥97 million respectively.

3. Consolidated Quarterly Financial Statements
(1) Consolidated Quarterly Balance Sheets

(Millions of Yen)

	As of Mar. 31, 2014	As of Sep. 30, 2014
Assets		
Current assets		
Cash and deposits	41,015	36,930
Notes and accounts receivable-trade	51,901	49,923
Securities	21,534	28,814
Merchandise and finished goods	26,729	28,028
Work in process	908	1,309
Raw materials and supplies	3,351	3,325
Other	5,254	6,150
Allowance for doubtful accounts	(143)	(148)
Total current assets	150,551	154,334
Noncurrent assets		
Property, plant and equipment	47,976	50,947
Intangible assets		
Goodwill	7,539	7,248
Other	4,123	3,999
Total intangible assets	11,662	11,247
Investments and other assets		
Investment securities	23,532	25,013
Other	5,077	5,213
Allowance for doubtful accounts	(223)	(224)
Total investments and other assets	28,386	30,001
Total noncurrent assets	88,025	92,196
Total assets	238,577	246,530
Liabilities		
Current liabilities		
Notes and accounts payable-trade	14,416	14,406
Short-term loans payable	5,914	5,646
Current portion of bonds	-	5,000
Accrued alcohol tax	8,376	7,308
Accrued expenses	4,480	4,405
Income taxes payable	5,621	912
Provision for bonuses	2,081	2,356
Other provision	1,817	1,711
Other	5,953	10,091
Total current liabilities	48,663	51,839
Noncurrent liabilities		
Bonds payable	25,000	20,000
Long-term loans payable	310	10,378
Net defined benefit liability	6,943	6,714
Long-term deposits received	5,591	5,628
Other	5,644	6,208
Total noncurrent liabilities	43,491	48,929
Total liabilities	92,154	100,769

(Millions of Yen)

	As of Mar. 31, 2014	As of Sep. 30, 2014
Net assets		
Shareholders' equity		
Capital stock	13,226	13,226
Capital surplus	3,196	3,196
Securities	104,739	104,769
Merchandise and finished goods	(9,931)	(9,936)
Total noncurrent assets	111,230	111,255
Accumulated other comprehensive income		
Valuation difference on available-for-sale securities	5,941	6,877
Deferred gains or losses on hedges	279	449
Foreign currency translation adjustment	2,894	1,360
Remeasurements of defined benefit plans	1,085	993
Total accumulated other comprehensive income	10,200	9,681
Minority interests	24,991	24,824
Total net assets	146,422	145,761
Total liabilities and net assets	238,577	246,530

(2) Consolidated Quarterly Statements of Income and Consolidated Quarterly Statements of Comprehensive Income

(Consolidated Quarterly Statements of Income)

(For the Six Months Ended September 30, 2014 and 2013) (Millions of Yen)

	FY2014 2Q (Apr. 1, 2013 – Sep. 30, 2013)	FY2015 2Q (Apr. 1, 2014 – Sep. 30, 2014)
Net sales	97.561	101,130
Cost of sales	60,608	62,502
Gross profit	36,953	38,627
Selling, general and administrative expenses	34,558	35,351
Operating income	2,395	3,275
Non-operating income		
Dividends income	198	236
Other	309	324
Total non-operating income	508	560
Non-operating expenses		
Interest expenses	223	247
Other	115	159
Total non-operating expenses	339	407
Ordinary income	2,564	3,429
Extraordinary income		
Gain on sales of subsidiaries and affiliates' stocks	9,261	-
Gain on sales of noncurrent assets	6	59
Gain on sales of investment securities	0	19
Other	75	-
Total extraordinary income	9,344	78
Extraordinary loss		
Loss on sales and retirement of noncurrent assets	43	128
Directors' retirement benefits	24	34
Other	0	1
Total extraordinary losses	68	164
Income before income taxes and minority interests	11,839	3,343
Income taxes-current	4,937	1,310
Income taxes-deferred	167	(76)
Total income taxes	5,104	1,233
Income before minority interests	6,734	2,110
Minority interests in income	125	281
Net income	6,609	1,828

(Consolidated Quarterly Statements of Comprehensive Income)
(For the Six Months Ended September 30, 2014 and 2013) (Millions of Yen)

	FY2014 2Q (Apr. 1, 2013 – Sep. 30, 2013)	FY2015 2Q (Apr. 1, 2014 – Sep. 30, 2014)
Income before minority interests	6,734	2,110
Other comprehensive income		
Valuation difference on available-for-sale securities	1,514	936
Deferred gains or losses on hedges	64	166
Foreign currency translation adjustment	3,149	(1,837)
Remeasurements of defined benefit plans	-	(92)
Share of other comprehensive income of associates accounted for using equity method	249	(87)
Gain or loss on change in equity	5,847	-
Total other comprehensive income	10,825	(913)
Comprehensive income	17,559	1,196
(Comprehensive income attributable to)		
Comprehensive income attributable to owners of the parent	16,715	1,309
Comprehensive income attributable to minority interests	844	(112)

(3) Consolidated Quarterly Statements of Cash Flows

(Millions of Yen)

	FY2014 2Q (Apr. 1, 2013 – Sep. 30, 2013)	FY2015 2Q (Apr. 1, 2014 – Sep. 30, 2014)
Net cash provided by (used in) operating activities		
Income before income taxes and minority interests	11,839	3,343
Depreciation and amortization	2,028	2,127
Interest and dividends income	(272)	(337)
Interest expenses	223	247
Loss (gain) on sales of stocks of subsidiaries and affiliates	(9,261)	-
Decrease (increase) in notes and accounts receivable-trade	1,560	1,772
Decrease (increase) in inventories	(2,907)	(1,937)
Increase (decrease) in notes and accounts payable-trade	122	40
Increase (decrease) in liquor taxes payable	(2,023)	(1,066)
Other, net	(773)	316
Subtotal	536	4,506
Interest and dividends income received	311	355
Interest expenses paid	(242)	(244)
Income taxes paid	(2,493)	(5,923)
Net cash provided by (used in) operating activities	(1,887)	(1,306)
Net cash provided by (used in) investing activities		
Payments into time deposits	(18,368)	(10,856)
Proceeds from withdrawal of time deposits	10,935	11,231
Purchase of securities	(1,695)	(3,880)
Proceeds from sales and redemption of securities	701	1,686
Purchase of property, plant and equipment and intangible assets	(3,085)	(3,045)
Proceeds from sales of stocks of subsidiaries and affiliates	12,241	-
Purchase of investments in subsidiaries resulting in change in scope of consolidation	(2,666)	(142)
Other, net	(56)	133
Net cash provided by (used in) investing activities	(1,989)	(4,873)
Net cash provided by (used in) financing activities		
Proceeds from long-term loans payable	-	10,100
Redemption of bonds	(5,000)	-
Proceeds from stock issuance to minority shareholders	11,420	-
Cash dividends paid	(1,823)	(2,211)
Other, net	(308)	(549)
Net cash provided by (used in) financing activities	4,288	7,339
Effect of exchange rate change on cash and cash equivalents	865	(471)
Net increase (decrease) in cash and cash equivalent	1,276	687
Cash and cash equivalents at beginning of period	35,287	34,608
Cash and cash equivalents at end of period	36,564	35,296

(4) Notes on Consolidated Quarterly Financial Statements

(Notes on Premise of Going Concern)

No items to report.

(Notes on Material Changes in Shareholders' Equity)

No items to report.

(Segment Information)

I. Equivalent Period of Previous Fiscal Year (From April 1, 2013, to September 30, 2013)

1. Net sales and Income (Loss) by Reported Segment

(Millions of yen)

	Reported Segment				Other (Note: 1)	Total	Adjustment (Note: 2)	Amount recognized in consolidated quarterly statements of income (Note: 3)
	Takara Shuzo Group	Takara Bio Group	Takara Healthcare	Subtotal				
Net sales								
External customers	85,540	9,986	673	96,200	1,147	97.347	213	97,561
Intersegment	172	290	1	463	2,329	2,793	(2,793)	-
Total	85,712	10,277	674	96,663	3,477	100,141	(2,579)	97,561
Segment income (loss)	1,463	454	(4)	1,913	103	2,017	377	2,395

Notes: 1. Other includes business segments that are not part of reported segments, such as the printing business and other subsidiaries.
2. Details of adjustment amounts are as follows.
(1) Net sales to external customers are income from real estate rent recognized by the Company.
(2) Segment income (loss) comprises intersegment eliminations of ¥39 million and income of the Company not allocated to business segments of ¥338 million.
3. Segment income (loss) has been adjusted to the operating income of consolidated quarterly statements of income.

2. Information on Impairment Loss on Noncurrent Assets, Goodwill, etc. by Reportable Segment

(Material impairment losses on noncurrent assets)

No items to report.

(Material changes in the amount of goodwill)

In the Takara Shuzo Group segment, goodwill increased ¥2,506 million in the six months ended September 30, 2014, due to factors including the acquisition of stock in newly consolidated T. Tazaki & Company Limited.

II. Period under Review (From April 1, 2014, to September 30, 2014)

1. Net sales and Income (Loss) by Reported Segment

(Millions of yen)

	Reported Segment				Other (Note: 1)	Total	Adjustment (Note: 2)	Amount recognized in consolidated quarterly statements of income (Note: 3)
	Takara Shuzo Group	Takara Bio Group	Takara Healthcare	Subtotal				
Net sales								
External customers	88,358	10,585	809	99,753	1,150	100,904	225	101,130
Intersegment	156	385	0	542	2,185	2,728	(2,728)	-
Total	88,515	10,971	810	100,296	3,336	103,632	(2,502)	101,130
Segment income	2,194	625	30	2,850	28	2,878	396	3,275

Notes: 1. Other includes business segments that are not part of reported segments, such as the printing business and other subsidiaries.
2. Details of adjustment amounts are as follows.
(1) Net sales to external customers are income from real estate rent recognized by the Company.
(2) Segment income comprises intersegment eliminations of ¥21 million and income of the Company not allocated to business segments of ¥375 million.
3. Segment income has been adjusted to the operating loss of consolidated quarterly statements of income.

2. Matters concerning Changes to Reporting Segments

(Change in Method of Depreciation for Property, Plant and Equipment)

Consolidated subsidiary Takara Bio Inc. previously applied declining balance depreciation to property, plant and equipment but switched to straight-line depreciation from the three months ended June 30, 2014.

With this change, segment income for the Takara Bio Group for the six months ended September 30, 2014 increased ¥97 million compared with the previous method of depreciation.

3. Information on Impairment Loss on Noncurrent Assets, Goodwill, etc. by Reportable Segment

No items to report.

平成27年3月期
第2四半期決算短信補足資料

Supplement for the Consolidated Financial Statements
for the Second Quarter Ended September 30, 2014

1. 宝ホールディングス(連結)
Takara Holdings Inc. -Consolidated-
   ① グループ別要約損益計算書
   Consolidated Statements of Income by Business Group (Summary)
   ② 要約貸借対照表
   Consolidated Balance Sheets (Summary)

2. 宝酒造グループ
Takara Shuzo Group
   ① 要約損益計算書
   Statements of Income (Summary)
   ② 要約貸借対照表
   Balance Sheets (Summary)

3. タカラバイオグループ
Takara Bio Group
   ① 要約損益計算書
   Statements of Income (Summary)
   ② 要約貸借対照表
   Balance Sheets (Summary)

4. 6年間の財務サマリー(グループ別)
Six-Year Financial Summary by Business Group

5. 平成27年3月期 業績予想
Financial forecast for the year ending March 31, 2015
   ① 宝ホールディングス(連結)
   Takara Holdings Inc. -Consolidated-
   ② 宝酒造グループ
   Takara Shuzo Group
   ③ タカラバイオグループ
   Takara Bio Group

宝ホールディングス株式会社
TAKARA HOLDINGS INC.

財務・IR部 Financial & Investor Relations Dept.
TEL 075(241)5124
FAX 075(241)5127
E-Mail ir@takara.co.jp

将来見通しに関する注意事項

この資料中の当社および当社グループの現在の計画、見通し、戦略、確信などのうち、歴史的事実でないものは、将来の業績に関する見通しであり、これらは現時点において入手可能な情報から得られた当社経営陣の判断に基づくものですが、重大なリスクや不確実性を含んでいる情報から得られた多くの仮定および考えに基づきなされたものであります。実際の業績は、さまざまな要素によりこれら予測とは大きく異なる結果となり得ることをご承知おきください。

実際の業績に影響を与える要素には、経済情勢、特に消費動向、為替レートの変動、法律・行政制度の変化、競合会社の価格・製品戦略による圧力、当社の既存製品および新製品の販売力の低下、生産中断、当社の知的所有権に対する侵害、急速な技術革新、重大な訴訟における不利な判決等がありますが、業績に影響を与える要素はこれらに限定されるものではありません。

Forward-Looking Statements

Statements in this document, other than those based on historical fact, concerning the current plans, prospects, strategies and expectations of the Company and its Group represent forecasts of future results. While such statements are based on the conclusions of management according to information available at the time of writing, they reflect many assumptions and opinions derived from information that includes major risks and uncertainties. Actual results may vary significantly from these forecasts due to various factors.

Factors that could influence actual results include, but are not limited to, economic conditions, especially trends in consumer spending, as well as exchange rate fluctuations, changes in laws and government systems, pressure from competitors' prices and product strategies, declines in selling power of the Company's existing and new products, disruptions to production, violations of the Company's intellectual property rights, rapid advances in technology and unfavorable verdicts in major litigation.

宝ホールディングス株式会社　財務・IR部
Takara Holdings Inc. Financial & Investor Relations Dept.

TEL 075(241)5124　FAX 075(241)5127
E-Mail ir@takara.co.jp

1. 宝ホールディングス(連結) :Takara Holdings Inc. -Consolidated-

① グループ別要約損益計算書 :Consolidated Statements of Income by Business Group (Summary)

(百万円 :Millions of Yen)

	平成26年3月期 第2四半期累計	平成27年3月期 第2四半期累計 Apr. 1, 2014 - Sep. 30, 2014		対前期 Change from FY2014(1Q-2Q)		対5/8予想 Difference from forecast announced May 2014	
	実績(a) FY2014(1Q-2Q) Actual (a)	5/8予想(b) FY2015(1Q-2Q) Forecast announced May 2014 (b)	実績(c) FY2015(1Q-2Q) Actual (c)	増減(c-a) Change (c-a)	比(c/a) YOY% (c/a)	増減(c-b) Difference (c-b)	比(c/b) % (c/b)
宝酒造 グループ Takara Shuzo Group	85,712	88,300	88,515	2,803	103.3%	215	100.2%
タカラバイオ グループ Takara Bio Group	10,277	11,038	10,971	694	106.8%	△ 67	99.4%
宝ヘルスケア Takara Healthcare Inc.	674	770	810	135	120.1%	40	105.2%
その他 Other, net	897	892	833	△ 64	92.9%	△ 58	93.5%
売上高 Net sales	97,561	101,000	101,130	3,568	103.7%	130	100.1%
売上原価 Cost of sales	60,608	63,000	62,502	1,894	103.1%	△ 497	99.2%
売上総利益 Gross profit	36,953	38,000	38,627	1,674	104.5%	627	101.7%
運送費、保管料 Transportation and storage	3,652	3,750	3,850	197	105.4%	100	102.7%
広告宣伝費 Advertising	2,001	1,650	1,612	△ 388	80.6%	△ 37	97.7%
販売促進費、販売促進引当金繰入 Sales promotion and allowance for s.p.	16,131	15,900	15,696	△ 435	97.3%	△ 203	98.7%
研究開発費 Research and development	1,578	1,900	1,575	△ 2	99.8%	△ 324	82.9%
管理費、その他 Other, net	11,193	12,230	12,616	1,422	112.7%	386	103.2%
販売費及び一般管理費 SG&A expenses	34,558	35,430	35,351	793	102.3%	△ 78	99.8%
宝酒造 グループ Takara Shuzo Group	1,463	1,600	2,194	730	149.9%	594	137.1%
タカラバイオ グループ Takara Bio Group	454	457	625	170	137.6%	168	136.8%
宝ヘルスケア Takara Healthcare Inc.	△ 4	8	30	35	—	22	387.3%
その他 Other, net	481	505	425	△ 56	88.3%	△ 79	84.2%
営業利益(△:損失) Operating income(Δ:loss)	2,395	2,570	3,275	880	136.8%	705	127.5%
受取利息・配当金 Interest and Dividends income	272	300	337	65	124.1%	37	112.6%
その他営業外収益 Other, net	235	200	222	△ 13	94.4%	22	111.3%
営業外収益 Non-operating income	508	500	560	52	110.4%	60	112.1%
支払利息 Interest and discounts expenses	223	300	247	23	110.5%	△ 52	82.5%
その他営業外費用 Other, net	115	200	159	44	138.5%	△ 40	79.9%
営業外費用 Non-operating expenses	339	500	407	67	120.0%	△ 92	81.4%
経常利益(△:損失) Ordinary income(Δ:loss)	2,564	2,570	3,429	865	133.7%	859	133.4%
特別利益 Extraordinary income	9,344	—	78	△ 9,265	0.8%	78	—
特別損失 Extraordinary loss	68	100	164	95	239.3%	64	164.2%
税金等調整前四半期純利益(△:損失) Income(Δ:loss) before income taxes	11,839	2,470	3,343	△ 8,495	28.2%	873	135.4%
法人税、住民税及び事業税 Current income taxes	4,937	970	1,310	△ 3,627	26.5%	263	127.1%
法人税等調整額 Deferred income taxes	167		△ 76	△ 244	—		
少数株主損益調整前四半期純利益(△:損失) Income(Δ:loss) before minority interests	6,734	1,500	2,110	△ 4,624	31.3%	610	140.7%
少数株主利益(△:損失) Minority interests in net income(Δ:loss)	125	250	281	156	224.7%	31	112.8%
四半期純利益(△:損失) Net income(Δ:loss)	6,609	1,250	1,828	△ 4,780	27.7%	578	146.3%
設備投資額(有形・無形) Capital expenditures	2,808		5,524	2,716	196.7%		
減価償却費(有形・無形) Depreciation and Amortization	2,028	2,100	2,127	98	104.9%	27	101.3%

営業外収益 Non-operating income	受取利息101、受取配当金236、持分法による投資利益62 など Interest income 101, Dividends income 236, Equity in earnings of affiliates 62, etc.
営業外費用 Non-operating expenses	支払利息104、社債利息143、シンジケートローン関連費用54 など Interest expense 104, Interest on bonds 143, Syndicate loan expenses 54, etc.
特別利益 Extraordinary income	固定資産売却益59 など (前期:関係会社株式売却益9,261 など) Gain on sales of noncurrent assets 59, etc. (FY2014(1Q-2Q): Gain on sales of stocks of subsidiaries and affiliates 9,261, etc.)
特別損失 Extraordinary loss	固定資産除売却損128 など Loss on sales and retirement of noncurrent assets 128, etc.

② 要約貸借対照表 :Consolidated Balance Sheets (Summary)

資産の部 :Assets　　（百万円 :Millions of Yen）

	平成26年3月期末 As of Mar. 31, 2014	平成27年3月期第2四半期末 As of Sep. 30, 2014	増減 Change	主な増減理由 Reference
（流動資産） (Total current assets)	150,551	154,334	3,782	（億円 :One hundred millions of Yen）
現金及び預金 Cash and deposits	41,015	36,930	△ 4,085	TH＋12.1、TS△27.2、TB△21.6
受取手形及び売掛金 Notes and accounts receivable-trade	51,901	49,923	△ 1,978	TS△3.5、TB△15.4
有価証券 Marketable securities	21,534	28,814	7,279	TH＋19.9、TS＋39.3、TB＋13.4
たな卸資産 Inventories	30,988	32,663	1,674	TS＋12.4、TB＋4.3
その他 Other current assets	5,254	6,150	895	
貸倒引当金 Allowance for doubtful accounts	△ 143	△ 148	△ 4	
（固定資産） (Total fixed assets)	88,025	92,196	4,171	
〔有形固定資産〕 [Property, plant and equipment]	47,976	50,947	2,971	
建物及び構築物 Buildings and structures	14,138	15,679	1,541	（当期の有形・無形固定資産の増減内訳） Reference of Property, plant and equipment and Intangible assets
機械装置及び運搬具 Machinery, equipment and vehicles	10,309	12,058	1,748	新規取得　＋55.2　（TS＋24.8、TB＋30.0） Newly purchases +55.2
土地 Land	17,418	17,501	83	減価償却　△21.2　（TS△14.6、TB△5.9） Depreciation Δ21.2
その他 Other property, plant and equipment	6,110	5,707	△ 402	その他増減　△8.4 Other, net △8.4
〔無形固定資産〕 [Intangible fixed assets]	11,662	11,247	△ 414	
のれん Goodwill	7,539	7,248	△ 290	
その他 Other intangible fixed assets	4,123	3,999	△ 124	
〔投資その他の資産〕 [Investments and other assets]	28,386	30,001	1,615	
投資有価証券 Investment securities	23,532	25,013	1,480	TH時価評価差額＋14.1 TH Valuation difference +14.1
その他 Other assets	5,077	5,213	135	
貸倒引当金 Allowance for doubtful accounts	△ 223	△ 224	△ 1	
資産合計 Total assets	238,577	246,530	7,953	

(TH=Takara Holdings Inc., TS=Takara Shuzo Group, TB=Takara Bio Group)

② 要約貸借対照表 :Consolidated Balance Sheets (Summary)

負債及び純資産 の部 :Liabilities and net assets　　（百万円 :Millions of Yen）

	平成26年3月期末 As of Mar. 31, 2014	平成27年3月期第2四半期末 As of Sep. 30, 2014	増減 Change	主な増減理由 Reference
(流動負債) (Total current liabilities)	48,663	51,839	3,176	（億円 :One hundred millions of Yen）
支払手形及び買掛金 Notes and accounts payable-trade	14,416	14,406	△ 10	
短期借入金 Short-term loans payable	5,914	5,646	△ 268	
1年内償還の社債 Current portion of bonds	―	5,000	5,000	TH＋50.0 (#10SB Redemption, May 2015)
未払酒税 Accrued alcohol tax	8,376	7,308	△ 1,067	TS△10.6
未払費用 Accrued expenses	4,480	4,405	△ 75	
その他 Other current liabilities	15,474	15,072	△ 402	
(固定負債) (Total non-current liabilities)	43,491	48,929	5,438	
社債 Bonds payable	25,000	20,000	△ 5,000	TH△50.0 (#10SB Redemption, May 2015)
長期借入金 Long-term loans payable	310	10,378	10,067	TH＋101.0
退職給付に係る負債 Net defined benefit liability	6,943	6,714	△ 229	
預り金 Deposits from customers	5,591	5,628	36	
その他 Other non-current liabilities	5,644	6,208	563	TH繰延税金負債＋5.1 TH Deferred tax liabilities +5.1
負債合計 Total liabilities	92,154	100,769	8,614	
資本金 Capital stock	13,226	13,226	―	
資本剰余金 Capital surplus	3,196	3,196	0	
利益剰余金 Retained earnings	104,739	104,769	29	
自己株式 Treasury stock	△ 9,931	△ 9,936	△ 5	
(株主資本) (Total owner's equity)	111,230	111,255	24	
その他有価証券評価差額金 Valuation difference on available-for-sale securities	5,941	6,877	936	TH＋8.6
繰延ヘッジ損益 Deffered gains or losses on hedges	279	449	169	
為替換算調整勘定 Translation adjustments	2,894	1,360	△ 1,534	TS△10.8、TB△7.2 USD=101.30JPY, EUR=133.21JPY, GBP=172.53JPY (Jun. 2014) USD=105.40JPY, EUR=145.04JPY, GBP=173.74JPY (Dec. 2013)
退職給付に係る調整累計額 Remeasurements of defined benefit plans	1,085	993	△ 91	
(その他の包括利益累計額) (Total valuation and translation adjustments)	10,200	9,681	△ 519	
(少数株主持分) (Minority interests)	24,991	24,824	△ 166	
純資産合計 Total net assets	146,422	145,761	△ 661	
負債純資産合計 Total liabilities and net assets	238,577	246,530	7,953	

(TH=Takara Holdings Inc., TS=Takara Shuzo Group, TB=Takara Bio Group)

2. 宝酒造グループ :Takara Shuzo Group

① 要約損益計算書 :Statements of Income (Summary)

（百万円 :Millions of Yen）

	平成26年3月期 第2四半期累計	平成27年3月期 第2四半期累計 Apr. 1, 2014 - Sep. 30, 2014		対前期 Change from FY2014(1Q-2Q)		対5/8予想 Difference from forecast announced May 2014	
	実績(a) FY2014(1Q-2Q) Actual (a)	5/8予想(b) FY2015(1Q-2Q) Forecast announced May 2014 (b)	実績(c) FY2015(1Q-2Q) Actual (c)	増減(c-a) Change (c-a)	比(c/a) YOY% (c/a)	増減(c-b) Difference (c-b)	比(c/b) % (c/b)
焼酎 Shochu	33,128	31,200	31,090	△ 2,038	93.8%	△ 109	99.6%
清酒 Sake	8,368	9,200	9,168	800	109.6%	△ 31	99.7%
ソフトアルコール飲料 Light-alcohol refreshers	14,467	14,100	13,375	△ 1,091	92.5%	△ 724	94.9%
その他酒類 Other liquors	5,986	6,300	6,335	348	105.8%	35	100.6%
本みりん Hon Mirin	6,811	6,500	6,465	△ 345	94.9%	△ 34	99.5%
その他調味料 Other seasonings	3,940	4,300	4,107	166	104.2%	△ 192	95.5%
原料用アルコール等 Raw alcohol	3,184	3,200	3,171	△ 12	99.6%	△ 28	99.1%
海外日本食材卸 Japanese food wholesale business in overseas markets	3,345	7,100	8,390	5,044	250.8%	1,290	118.2%
その他 Other	6,478	6,400	6,409	△ 68	98.9%	9	100.2%
売上高 Net sales	85,712	88,300	88,515	2,803	103.3%	215	100.2%
売上原価 Cost of sales	55,239	57,200	56,846	1,607	102.9%	△ 353	99.4%
売上総利益 Gross profit	30,473	31,100	31,668	1,195	103.9%	568	101.8%
運送費、保管料 Transportation and storage	3,343	3,500	3,497	153	104.6%	△ 2	99.9%
広告宣伝費 Advertising	1,782	1,400	1,396	△ 385	78.3%	△ 3	99.7%
販売促進費、販売促進引当金繰入 Sales promotion and allowance for s.p.	15,600	15,400	15,246	△ 353	97.7%	△ 153	99.0%
研究開発費 Research and development	166	200	165	△ 0	99.9%	△ 34	83.0%
管理費、その他 Other, net	8,116	9,000	9,168	1,051	113.0%	168	101.9%
販売費及び一般管理費 SG&A expenses	29,009	29,500	29,474	465	101.6%	△ 25	99.9%
営業利益（△：損失） Operating income(Δ:loss)	1,463	1,600	2,194	730	149.9%	594	137.1%
営業外収益 Non-operating income	234	200	299	65	127.9%	99	149.6%
営業外費用 Non-operating expenses	99	200	207	108	208.9%	7	103.8%
経常利益（△：損失） Ordinary income(Δ:loss)	1,598	1,600	2,285	687	143.0%	685	142.9%
特別利益 Extraordinary gain	8	—	58	50	677.1%	58	—
特別損失 Extraordinary loss	39	100	143	103	362.7%	43	143.3%
税金等調整前四半期純利益（△：損失） Income(Δ:loss) before income taxes	1,567	1,500	2,201	633	140.4%	701	146.8%
法人税、住民税及び事業税 Current income taxes	817	650	732	△ 84	89.7%	135	120.9%
法人税等調整額 Deferred income taxes	△ 35		52	88	—		
少数株主損益調整前四半期純利益（△：損失） Income(Δ:loss) before minority interests	786	850	1,415	629	180.1%	565	166.6%
少数株主利益（△：損失） Minority interests in net income(Δ:loss)	64	100	133	69	208.8%	33	134.0%
四半期純利益（△：損失） Net income(Δ:loss)	721	750	1,281	559	177.5%	531	170.9%
設備投資額（有形・無形） Capital expenditures	930		2,481	1,551	266.7%		
減価償却費（有形・無形） Depreciation and Amortization	1,397	1,450	1,463	66	104.7%	13	100.9%

*平成26年3月期の実績において、「その他」の一部を「その他酒類」と「海外日本食材卸」にそれぞれ組替えております。
（平成27年3月期の区分に合わせております。）

② 要約貸借対照表 :Balance Sheets (Summary)

資産の部 :Assets　　（百万円 :Millions of Yen）

	平成26年3月期末 As of Mar. 31, 2014	平成27年3月期第2四半期末 As of Sep. 30, 2014	増減 Change	主な増減理由 Reference
（流動資産） (Total current assets)	94,808	96,855	2,046	（億円 :One hundred millions of Yen）
現金及び預金 Cash and deposits	12,961	10,231	△ 2,729	米国宝ホールディング△39.9、宝酒造△4.1、宝ヨーロッパホールディングス＋13.6 USA Takara Holding Δ39.9, Takara Shuzo Δ4.1, Takara Europe Holdings +13.6
受取手形及び売掛金 Notes and accounts receivable-trade	45,088	44,730	△ 357	
有価証券 Marketable securities	5,402	9,336	3,933	米国宝ホールディング＋37.2 USA Takara Holding +37.2
たな卸資産 Inventories	26,447	27,687	1,240	宝酒造＋5.3、ラック・コーポレーション＋4.7、トマーチン＋2.6 Takara Shuzo +5.3, Luc Corporation +4.7, The Tomatin Disillery +2.6
その他 Other current assets	5,014	4,978	△ 36	
貸倒引当金 Allowance for doubtful accounts	△ 105	△ 108	△ 3	
（固定資産） (Total fixed assets)	44,652	45,235	583	
〔有形固定資産〕 [Property, plant and equipment]	26,997	27,929	931	
建物及び構築物 Buildings and structures	9,474	9,221	△ 252	（当期の有形・無形固定資産の増減内訳） Reference of Property, plant and equipment and Intangible assets
機械装置及び運搬具 Machinery, equipment and vehicles	8,686	9,301	614	新規取得 ＋24.8 Newly purchases +24.8
土地 Land	7,021	7,086	64	減価償却 △14.6 Depreciation Δ14.6
その他 Other property, plant and equipment	1,815	2,320	504	その他増減 △5.5 Other, net Δ5.5
〔無形固定資産〕 [Intangible fixed assets]	9,028	8,562	△ 466	
のれん Goodwill	6,061	5,681	△ 379	
その他 Other intangible fixed assets	2,967	2,881	△ 86	
〔投資その他の資産〕 [Investments and other assets]	8,625	8,743	117	
投資有価証券 Investment securities	5,178	5,281	102	
その他 Other assets	3,534	3,549	14	
貸倒引当金 Allowance for doubtful accounts	△ 87	△ 86	0	
資産合計 Total assets	139,460	142,090	2,630	

② 要約貸借対照表 :Balance Sheets (Summary)

負債及び純資産 の部 :Liabilities and net assets

（百万円 :Millions of Yen）

	平成26年3月期末 As of Mar. 31, 2014	平成27年3月期第2四半期末 As of Sep. 30, 2014	増減 Change	主な増減理由 Reference
(流動負債) (Total current liabilities)	41,153	43,242	2,088	（億円 :One hundred millions of Yen）
支払手形及び買掛金 Notes and accounts payable-trade	11,626	11,918	291	
短期借入金 Short-term loans payable	7,682	10,002	2,319	宝酒造＋20.0、ラック・コーポレーション＋3.8、タザキフーズ△1.9 Takara Shuzo +20.0, Luc Corporation +3.8, Tazaki Foods△1.9
未払酒税 Accrued alcohol tax	8,376	7,308	△ 1,067	宝酒造△10.6 Takara Shuzo Δ10.6
未払費用 Accrued expenses	3,736	3,925	188	
販売促進引当金 Reserve for sales promotion expenses	1,795	1,697	△ 98	
その他 Other current liabilities	7,935	8,389	453	
(固定負債) (Total non-current liabilities)	15,339	15,150	△ 188	
長期借入金 Long-term loans payable	1,797	1,843	46	
退職給付に係る負債 Net defined benefit liability	6,385	6,146	―	
預り金 Deposits from customers	5,480	5,473	△ 7	
その他 Other non-current liabilities	1,674	1,686	11	
負債合計 Total liabilities	56,492	58,392	1,900	
資本金 Capital stock	1,000	1,000	―	
資本剰余金 Capital surplus	56,678	56,678	―	
利益剰余金 Retained earnings	19,445	21,108	1,662	
(株主資本) (Total owner's equity)	77,123	78,786	1,662	
その他有価証券評価差額金 Valuation difference on available-for-sale securities	144	207	62	
繰延ヘッジ損益 Deffered gains or losses on hedges	279	449	169	
為替換算調整勘定 Translation adjustments	1,721	631	△ 1,089	Translation Rate USD=101.30JPY, EUR=133.21JPY, GBP=172.53JPY (Jun. 2014) USD=105.40JPY, EUR=145.04JPY, GBP=173.74JPY (Dec. 2013)
退職給付に係る調整累計額 Remeasurements of defined benefit plans	1,054	967	―	
(その他の包括利益累計額) (Total valuation and translation adjustments)	3,200	2,255	△ 944	
(少数株主持分) (Minority interests)	2,643	2,655	12	
純資産合計 Total net assets	82,967	83,697	730	
負債純資産合計 Total liabilities and net assets	139,460	142,090	2,630	

3. タカラバイオグループ :Takara Bio Group

① 要約損益計算書 :Statements of Income (Summary)

（百万円 :Millions of Yen）

	平成26年3月期 第2四半期累計	平成27年3月期 第2四半期累計 Apr. 1, 2014 - Sep. 30, 2014		対前期 Change from FY2014(1Q-2Q)		対5/8予想 Difference from forecast announced May 2014	
	実績(a) FY2014(1Q-2Q) Actual (a)	5/8予想(b) FY2015(1Q-2Q) Forecast announced May 2014 (b)	実績(c) FY2015(1Q-2Q) Actual (c)	増減(c-a) Change (c-a)	比(c/a) YOY% (c/a)	増減(c-b) Difference (c-b)	比(c/b) % (c/b)
研究用試薬 Research reagents	7,094	7,647	7,789	694	109.8%	141	101.9%
理化学機器 Scientific instruments	1,061	1,065	985	△ 76	92.8%	△ 80	92.4%
受託・その他 Contracted service and other	1,187	1,252	1,168	△ 19	98.4%	△ 84	93.3%
バイオ産業支援　計 Bioindustry	9,343	9,965	9,942	598	106.4%	△ 23	99.8%
遺伝子医療 Gene Therapy	—	—	—	—	—	—	—
医食品バイオ AgriBio	933	1,073	1,029	95	110.2%	△ 44	95.9%
売上高 Net sales	10,277	11,038	10,971	694	106.8%	△ 67	99.4%
売上原価 Cost of sales	4,673	4,959	4,916	243	105.2%	△ 42	99.1%
売上総利益 Gross profit	5,603	6,079	6,054	451	108.1%	△ 24	99.6%
運送費、保管料 Transportation and storage	256	265	297	40	115.8%	31	111.8%
広告宣伝費 Advertising	69	65	52	△ 16	76.8%	△ 12	80.4%
販売促進費 Sales promotion	497	467	409	△ 88	82.2%	△ 57	87.6%
研究開発費 Research and development	1,407	1,678	1,402	△ 5	99.6%	△ 275	83.6%
管理費、その他 Other, net	2,917	3,145	3,267	349	112.0%	121	103.9%
販売費及び一般管理費 SG&A expenses	5,148	5,622	5,429	280	105.4%	△ 193	96.6%
バイオ産業支援 Bioindustry	1,875	1,926	2,044	168	109.0%	117	106.1%
遺伝子医療 Gene Therapy	△ 415	△ 563	△ 435	△ 20	—	128	—
医食品バイオ AgriBio	△ 188	△ 107	△ 223	△ 35	—	△ 116	—
共通 Eliminations/Corporate	△ 816	△ 797	△ 759	57	—	38	—
営業利益(△:損失) Operating income(Δ:loss)	454	457	625	170	137.6%	168	136.8%
営業外収益 Non-operating income	113	76	104	△ 8	92.2%	28	136.9%
営業外費用 Non-operating expenses	74	39	29	△ 45	39.0%	△ 10	73.9%
経常利益(△:損失) Ordinary income(Δ:loss)	493	494	701	207	142.0%	206	141.8%
特別利益 Extraordinary income	0	—	—	△ 0	—	—	—
特別損失 Extraordinary loss	26	21	16	△ 9	62.9%	△ 4	78.1%
税金等調整前四半期純利益(△:損失) Income(Δ:loss) before income taxes	467	472	684	217	146.5%	211	144.7%
法人税、住民税及び事業税 Current income taxes	402	198	558	155	138.7%	92	146.5%
法人税等調整額 Deferred income taxes	△ 157		△ 267	△ 110	—		
少数株主損益調整前四半期純利益(△:損失) Income(Δ:loss) before minority interests	222	274	393	171	176.9%	119	143.4%
少数株主利益(△:損失) Minority interests in net income(Δ:loss)	△ 5	△ 2	△ 10	△ 5	—	△ 8	—
四半期純利益(△:損失) Net income(Δ:loss)	227	276	404	176	177.6%	127	146.1%
設備投資額(有形・無形) Capital expenditures	1,846		3,008	1,161	162.9%		
減価償却費(有形・無形) Depreciation and Amortization	552	624	592	39	107.1%	△ 32	94.8%

*平成26年3月期の実績は、平成26年4月の組織改正後の新しい事業セグメントで算出しています。
（平成27年3月期の区分に合わせております。）

② 要約貸借対照表 :Balance Sheets (Summary)

資産の部 :Assets

（百万円 :Millions of Yen）

	平成26年3月期末 As of Mar. 31, 2014	平成27年3月期第2四半期末 As of Sep. 30, 2014	増減 Change	主な増減理由 Reference
（流動資産） (Total current assets)	41,817	40,425	△ 1,391	（億円 :One hundred millions of Yen）
現金及び預金 Cash and deposits	21,302	19,134	△ 2,168	タカラバイオ△13.1、宝生物工程（大連）△7.6 Takara Bio △13.1, Takara Biotechnology (Dalian) △7.6
受取手形及び売掛金 Notes and accounts receivable-trade	6,271	4,726	△ 1,545	タカラバイオ△19.5 Takara Bio Δ19.5
有価証券 Marketable securities	8,631	9,977	1,346	タカラバイオ＋13.0 Takara Bio +13.0
たな卸資産 Inventories	4,421	4,851	430	タカラバイオ＋5.5 Takara Bio +5.5
その他 Other current assets	1,227	1,774	546	繰延税金資産＋1.9 Deferred tax assets +1.9
貸倒引当金 Allowance for doubtful accounts	△ 37	△ 38	△ 0	
（固定資産） (Total fixed assets)	20,682	23,142	2,459	
〔有形固定資産〕 [Property, plant and equipment]	16,960	19,244	2,283	
建物及び構築物 Buildings and structures	3,863	5,886	2,023	（当期の有形・無形固定資産の増減内訳） Reference of Property, plant and equipment and Intangible assets
機械装置及び運搬具 Machinery, equipment and vehicles	1,522	2,668	1,145	新規取得 ＋30.0 Newly purchases +30.0
土地 Land	7,673	7,691	18	減価償却 △5.9 Depreciation Δ5.9
その他 Other property, plant and equipment	3,901	2,997	△ 903	その他増減 △0.8 Other, net △0.8
〔無形固定資産〕 [Intangible fixed assets]	2,587	2,637	50	
のれん Goodwill	1,477	1,567	89	
その他 Other intangible fixed assets	1,109	1,070	△ 39	
〔投資その他の資産〕 [Investments and other assets]	1,135	1,260	125	
長期前払費用 Long-term prepaid expenses	977	978	1	
その他 Other assets	192	317	125	
貸倒引当金 Allowance for doubtful accounts	△ 34	△ 35	△ 0	
資産合計 Total assets	62,500	63,567	1,067	

② 要約貸借対照表 :Balance Sheets (Summary)

負債及び純資産 の部 :Liabilities and net assets

（百万円 :Millions of Yen）

	平成26年3月期末 As of Mar. 31, 2014	平成27年3月期第2四半期末 As of Sep. 30, 2014	増減 Change	主な増減理由 Reference
（流動負債） (Total current liabilities)	4,372	5,861	1,488	（億円 :One hundred millions of Yen）
支払手形及び買掛金 Notes and accounts payable-trade	1,551	1,684	133	タカラバイオ＋1.3 Takara Bio +1.3
短期借入金 Short-term loans payable	136	137	0	
その他 Other current liabilities	2,685	4,039	1,353	未払金＋13.3 Accounts payable-other +13.3
（固定負債） (Total non-current liabilities)	1,000	1,019	19	
長期借入金 Long-term loans payable	225	211	△ 14	
退職給付に係る負債 Net defined benefit liability	294	325	—	
預り金 Deposits from customers	—	—	—	
その他 Other non-current liabilities	479	483	3	
負債合計 Total liabilities	5,372	6,880	1,508	
資本金 Capital stock	14,965	14,965	—	
資本剰余金 Capital surplus	32,893	32,893	—	
利益剰余金 Retained earnings	7,280	7,582	302	
自己株式 Treasury stock	—	—	—	
（株主資本） (Total owner's equity)	55,139	55,442	302	
その他有価証券評価差額金 Valuation difference on available-for-sale securities	—	—	—	
繰延ヘッジ損益 Deffered gains or losses on hedges	—	—	—	
為替換算調整勘定 Translation adjustments	1,926	1,196	△ 729	Translation Rate USD=98.63JPY, EUR=128.56JPY, CNY=16.07JPY (Jun. 2013) USD=86.58JPY, EUR=114.69JPY, CNY=13.91JPY (Dec. 2012)
退職給付に係る調整累計額 Remeasurements of defined benefit plans	2	0	—	
（その他の包括利益累計額） (Total valuation and translation adjustments)	1,928	1,197	△ 731	
（少数株主持分） (Minority interests)	58	47	△ 11	
純資産合計 Total net assets	57,127	56,686	△ 440	
負債純資産合計 Total liabilities and net assets	62,500	63,567	1,067	

4. 6年間の財務サマリー（グループ別） :Six-Year Financial Summary by Business Group

宝ホールディングス（連結） :Takara Holdings Inc. -Consolidated-

（百万円 :Millions of Yen）

		平成22年3月期 第2四半期累計 FY2010(1Q-2Q)	平成23年3月期 第2四半期累計 FY2011(1Q-2Q)	平成24年3月期 第2四半期累計 FY2012(1Q-2Q)	平成25年3月期 第2四半期累計 FY2013(1Q-2Q)	平成26年3月期 第2四半期累計 FY2014(1Q-2Q)	平成27年3月期 第2四半期累計 FY2015(1Q-2Q)	前期対比 Change from FY2014(1Q-2Q) 増減 Change	比 YOY%
売上高	Net sales	91,125	91,472	95,478	95,711	97,561	101,130	3,568	103.7%
売上原価	Cost of sales	56,205	56,068	58,583	59,163	60,608	62,502	1,894	103.1%
（売上高原価率）	(Ratio to Net sales)	61.7%	61.3%	61.4%	61.8%	62.1%	61.8%	-0.3pt	–
売上総利益	Gross profit	34,919	35,404	36,895	36,548	36,953	38,627	1,674	104.5%
販売費及び一般管理費	SG&A expenses	31,982	32,155	33,569	33,648	34,558	35,351	793	102.3%
（売上高販管費率）	(Ratio to Net sales)	35.1%	35.2%	35.2%	35.2%	35.4%	35.0%	-0.5pt	–
営業利益（△：損失）	Operating income(Δ:loss)	2,937	3,248	3,326	2,899	2,395	3,275	880	136.8%
（売上高営業利益率）	(Ratio to Net Sales)	3.2%	3.6%	3.5%	3.0%	2.5%	3.2%	+0.8pt	–
販売促進費、販売促進引当金繰入	Sales promotion and allowance for s.p.	14,660	14,872	15,551	15,914	16,131	15,696	Δ 435	97.3%
（売上高販促費率）	(Ratio to Net sales)	16.1%	16.3%	16.3%	16.6%	16.5%	15.5%	-1.0pt	–
研究開発費	R&D expenses	1,684	1,424	1,440	1,489	1,578	1,575	Δ 2	99.8%
（売上高研究開発費率）	(Ratio to Net sales)	1.8%	1.6%	1.5%	1.6%	1.6%	1.6%	-0.1pt	–
設備投資額（有形・無形）	Capital expenditures	1,640	1,515	2,746	2,254	2,808	5,524	2,716	196.7%
減価償却費（有形・無形）	Depreciation and Amortization	2,374	2,200	2,151	2,052	2,028	2,127	98	104.9%

宝酒造グループ :Takara Shuzo Group

（百万円 :Millions of Yen）

		平成22年3月期 第2四半期累計 FY2010(1Q-2Q)	平成23年3月期 第2四半期累計 FY2011(1Q-2Q)	平成24年3月期 第2四半期累計 FY2012(1Q-2Q)	平成25年3月期 第2四半期累計 FY2013(1Q-2Q)	平成26年3月期 第2四半期累計 FY2014(1Q-2Q)	平成27年3月期 第2四半期累計 FY2015(1Q-2Q)	前期対比 Change from FY2014(1Q-2Q) 増減 Change	比 YOY%
売上高	Net sales	80,153	80,754	84,996	84,909	85,712	88,515	2,803	103.3%
売上原価	Cost of sales	50,732	50,771	53,752	54,287	55,239	56,846	1,607	102.9%
（売上高原価率）	(Ratio to Net sales)	63.3%	62.9%	63.2%	63.9%	64.4%	64.2%	-0.2pt	–
売上総利益	Gross profit	29,420	29,982	31,244	30,622	30,473	31,668	1,195	103.9%
販売費及び一般管理費	SG&A expenses	26,882	27,198	28,674	28,608	29,009	29,474	465	101.6%
（売上高販管費率）	(Ratio to Net sales)	33.5%	33.7%	33.7%	33.7%	33.8%	33.3%	-0.5pt	–
営業利益（△：損失）	Operating income(Δ:loss)	2,537	2,784	2,569	2,014	1,463	2,194	730	149.9%
（売上高営業利益率）	(Ratio to Net sales)	3.2%	3.4%	3.0%	2.4%	1.7%	2.5%	+0.8pt	–
販売促進費、販売促進引当金繰入	Sales promotion and allowance for s.p.	14,078	14,409	15,083	15,450	15,600	15,246	Δ 353	97.7%
（売上高販促費率）	(Ratio to Net sales)	17.6%	17.8%	17.7%	18.2%	18.2%	17.2%	-1.0pt	–
設備投資額（有形・無形）	Capital expenditures	1,164	1,060	1,081	1,220	930	2,481	1,551	266.7%
減価償却費（有形・無形）	Depreciation and Amortization	1,676	1,565	1,550	1,444	1,397	1,463	66	104.7%

タカラバイオグループ :Takara Bio Group

（百万円 :Millions of Yen）

		平成22年3月期 第2四半期累計 FY2010(1Q-2Q)	平成23年3月期 第2四半期累計 FY2011(1Q-2Q)	平成24年3月期 第2四半期累計 FY2012(1Q-2Q)	平成25年3月期 第2四半期累計 FY2013(1Q-2Q)	平成26年3月期 第2四半期累計 FY2014(1Q-2Q)	平成27年3月期 第2四半期累計 FY2015(1Q-2Q)	前期対比 Change from FY2014(1Q-2Q) 増減 Change	比 YOY%
売上高	Net sales	8,690	8,443	8,642	9,013	10,277	10,971	694	106.8%
売上原価	Cost of sales	4,110	3,960	3,873	3,961	4,673	4,916	243	105.2%
（売上高原価率）	(Ratio to Net sales)	47.3%	46.9%	44.8%	43.9%	45.5%	44.8%	-0.7pt	–
売上総利益	Gross profit	4,580	4,483	4,768	5,052	5,603	6,054	451	108.1%
販売費及び一般管理費	SG&A expenses	4,589	4,288	4,374	4,628	5,148	5,429	280	105.4%
（売上高販管費率）	(Ratio to Net sales)	52.8%	50.8%	50.6%	51.4%	50.1%	49.5%	-0.6pt	–
営業利益（△：損失）	Operating income(Δ:loss)	Δ 9	194	394	423	454	625	170	137.6%
（売上高営業利益率）	(Ratio to Net sales)	–	2.3%	4.6%	4.7%	4.4%	5.7%	+1.3pt	–
研究開発費	R&D expenses	1,502	1,240	1,258	1,310	1,407	1,402	Δ 5	99.6%
（売上高研究開発費率）	(Ratio to Net sales)	17.3%	14.7%	14.6%	14.5%	13.7%	12.8%	-0.9pt	–
設備投資額（有形・無形）	Capital expenditures	448	402	403	765	1,846	3,008	1,161	162.9%
減価償却費（有形・無形）	Depreciation and Amortization	626	562	532	536	552	592	39	107.1%

宝ヘルスケア :Takara Healthcare Inc.

（百万円 :Millions of Yen）

		平成22年3月期 第2四半期累計 FY2010(1Q-2Q)	平成23年3月期 第2四半期累計 FY2011(1Q-2Q)	平成24年3月期 第2四半期累計 FY2012(1Q-2Q)	平成25年3月期 第2四半期累計 FY2013(1Q-2Q)	平成26年3月期 第2四半期累計 FY2014(1Q-2Q)	平成27年3月期 第2四半期累計 FY2015(1Q-2Q)	前期対比 Change from FY2014(1Q-2Q) 増減 Change	比 YOY%
売上高	Net sales	1,544	1,516	1,326	1,135	674	810	135	120.1%
売上原価	Cost of sales	1,146	1,062	879	732	318	396	77	124.4%
（売上高原価率）	(Ratio to Net sales)	74.2%	70.1%	66.3%	64.5%	47.2%	48.9%	+1.7pt	–
売上総利益	Gross profit	398	453	447	403	356	413	57	116.2%
販売費及び一般管理費	SG&A expenses	564	569	533	406	360	382	22	106.2%
（売上高販管費率）	(Ratio to Net sales)	36.6%	37.5%	40.2%	35.8%	53.4%	47.3%	-6.2pt	–
営業利益（△：損失）	Operating income(Δ:loss)	Δ 166	Δ 115	Δ 86	Δ 3	Δ 4	30	35	–
（売上高営業利益率）	(Ratio to Net sales)	–	–	–	–	–	3.8%	–	–
ヘルスケア事業売上高	Net sales of Healthcare products	384	530	580	608	674	810	135	120.1%
設備投資額（有形・無形）	Capital expenditures	–	–	26	0	1	2	0	151.8%
減価償却費（有形・無形）	Depreciation and Amortization	4	5	5	5	0	0	0	600.4%

5. 平成27年3月期 業績予想 :Financial forecast for the year ending March 31, 2015

① 宝ホールディングス(連結) :Takara Holdings Inc. -Consolidated-

(百万円 :Millions of Yen)

	平成26年3月期 FY2014	平成27年3月期 FY2015_Apr. 1, 2014 - Mar. 31, 2015		対前期 Change from FY2014		対5/8予想 Change from forecast announced May 2014	
	実績(a) Actual (a)	5/8予想(b) Forecast announced May 2014 (b)	11/5予想(c) Forecast announced Nov. 2014 (c)	増減(c-a) Change (c-a)	比(c/a) % (c/a)	増減(c-b) Change (c-b)	比(c/b) % (c/b)
宝酒造 グループ Takara Shuzo Group	182,306	189,500	189,300	6,993	103.8%	△ 200	99.9%
タカラバイオ グループ Takara Bio Group	23,905	25,200	25,200	1,294	105.4%	—	100.0%
宝ヘルスケア Takara Healthcare Inc.	1,424	1,580	1,600	175	112.3%	20	101.3%
その他 Other, net	1,931	1,720	1,900	△ 31	98.4%	180	110.5%
売上高 Net sales	209,568	218,000	218,000	8,431	104.0%	—	100.0%
売上原価 Cost of sales	129,447	134,000	133,700	4,252	103.3%	△ 300	99.8%
売上総利益 Gross profit	80,121	84,000	84,300	4,178	105.2%	300	100.4%
運送費、保管料 Transportation and storage	7,708	8,000	8,300	591	107.7%	300	103.8%
広告宣伝費 Advertising	3,546	3,600	3,600	53	101.5%	—	100.0%
販売促進費、販売促進引当金繰入 Sales promotion and allowance for s.p.	32,954	33,500	33,500	545	101.7%	—	100.0%
研究開発費 Research and development	3,376	4,000	3,800	423	112.5%	△ 200	95.0%
管理費、その他 Other, net	23,044	25,100	25,300	2,255	109.8%	200	100.8%
販売費及び一般管理費 SG&A expenses	70,631	74,200	74,500	3,868	105.5%	300	100.4%
宝酒造 グループ Takara Shuzo Group	6,329	6,800	6,800	470	107.4%	—	100.0%
タカラバイオ グループ Takara Bio Group	1,954	2,000	2,000	46	102.4%	—	100.0%
宝ヘルスケア Takara Healthcare Inc.	21	30	30	8	139.6%	—	100.0%
その他 Other,net	1,184	970	970	△ 214	81.9%	—	100.0%
営業利益(△:損失) Operating income(Δ:loss)	9,490	9,800	9,800	309	103.3%	—	100.0%
受取利息・配当金 Interest and Dividends income	562	600	600	37	106.7%	—	100.0%
その他営業外収益 Other, net	559	500	500	△ 59	89.3%	—	100.0%
営業外収益 Non-operating income	1,122	1,100	1,100	△ 22	98.0%	—	100.0%
支払利息 Interest and discounts expenses	464	600	600	135	129.2%	—	100.0%
その他営業外費用 Other, net	238	300	300	61	125.7%	—	100.0%
営業外費用 Non-operating expenses	703	900	900	196	128.0%	—	100.0%
経常利益(△:損失) Ordinary income(Δ:loss)	9,909	10,000	10,000	90	100.9%	—	100.0%
特別利益 Extraordinary income	9,565	—	—	△ 9,565	—	—	—
特別損失 Extraordinary loss	832	300	300	△ 532	36.0%	—	100.0%
税金等調整前当期純利益(△:損失) Income(Δ:loss) before income taxes	18,642	9,700	9,700	△ 8,942	52.0%	—	100.0%
法人税、住民税及び事業税 Current income taxes	7,140	3,700	3,700	△ 3,935	48.5%	—	100.0%
法人税等調整額 Deferred income taxes	495						
少数株主損益調整前当期純利益(△:損失) Income(Δ:loss) before minority interests	11,006	6,000	6,000	△ 5,006	54.5%	—	100.0%
少数株主利益(△:損失) Minority interests in net income(Δ:loss)	726	700	700	△ 26	96.4%	—	100.0%
当期純利益(△:損失) Net income(Δ:loss)	10,280	5,300	5,300	△ 4,980	51.6%	—	100.0%
設備投資額(有形・無形) Capital expenditures	8,967	10,337	10,337	1,370	115.3%	—	100.0%
減価償却費(有形・無形) Depreciation and Amortization	4,287	4,400	4,300	12	100.3%	△ 100	97.7%

② 宝酒造グループ :Takara Shuzo Group

（百万円 :Millions of Yen）

	平成26年3月期 FY2014	平成27年3月期 FY2015_Apr. 1, 2014 - Mar. 31, 2015		対前期 Change from FY2014		対5/8予想 Change from forecast announced May 2014	
	実績(a) Actual (a)	5/8予想(b) Forecast announced May 2014 (b)	11/5予想(c) Forecast announced Nov. 2014 (c)	増減(c-a) Change (c-a)	比(c/a) % (c/a)	増減(c-b) Change (c-b)	比(c/b) % (c/b)
焼酎 Shochu	65,977	63,900	62,500	△ 3,477	94.7%	△ 1,400	97.8%
清酒 Sake	23,513	26,300	26,300	2,786	111.9%	—	100.0%
ソフトアルコール飲料 Light-alcohol refreshers	26,772	27,400	26,000	△ 772	97.1%	△ 1,400	94.9%
その他酒類 Other liquors	12,583	12,800	12,500	△ 83	99.3%	△ 300	97.7%
本みりん Hon Mirin	14,886	14,300	14,300	△ 586	96.1%	—	100.0%
その他調味料 Other seasonings	8,645	9,300	9,000	354	104.1%	△ 300	96.8%
原料用アルコール等 Raw alcohol	6,899	7,300	7,700	800	111.6%	400	105.5%
海外日本食材卸 Japanese food wholesale business in overseas markets	9,077	14,500	16,900	7,822	186.2%	2,400	116.6%
その他 Other	13,950	13,700	14,100	149	101.1%	400	102.9%
売上高 Net sales	182,306	189,500	189,300	6,993	103.8%	△ 200	99.9%
売上原価 Cost of sales	116,619	121,000	120,400	3,780	103.2%	△ 600	99.5%
売上総利益 Gross profit	65,686	68,500	68,900	3,213	104.9%	400	100.6%
運送費、保管料 Transportation and storage	7,067	7,400	7,600	532	107.5%	200	102.7%
広告宣伝費 Advertising	3,115	3,100	3,100	△ 15	99.5%	—	100.0%
販売促進費、販売促進引当金繰入 Sales promotion and allowance for s.p.	31,889	32,500	32,500	610	101.9%	—	100.0%
研究開発費 Research and development	341	400	400	58	117.1%	—	100.0%
管理費、その他 Other, net	16,943	18,300	18,500	1,556	109.2%	200	101.1%
販売費及び一般管理費 SG&A expenses	59,357	61,700	62,100	2,742	104.6%	400	100.6%
営業利益(△:損失) Operating income(Δ:loss)	6,329	6,800	6,800	470	107.4%	—	100.0%
営業外収益 Non-operating income	466	400	400	△ 66	85.7%	—	100.0%
営業外費用 Non-operating expenses	321	300	300	△ 21	93.2%	—	100.0%
経常利益(△:損失) Ordinary income(Δ:loss)	6,474	6,900	6,900	425	106.6%	—	100.0%
特別利益 Extraordinary income	139	—	—	△ 139	—	—	—
特別損失 Extraordinary loss	595	200	200	△ 395	33.6%	—	100.0%
税金等調整前当期純利益(△:損失) Income(Δ:loss) before income taxes	6,018	6,700	6,700	681	111.3%	—	100.0%
法人税、住民税及び事業税 Current income taxes	2,636	2,650	2,650	△ 126	95.4%	—	100.0%
法人税等調整額 Deferred income taxes	140						
少数株主損益調整前当期純利益(△:損失) Income(Δ:loss) before minority interests	3,241	4,050	4,050	808	124.9%	—	100.0%
少数株主利益(△:損失) Minority interests in net income(Δ:loss)	188	200	200	11	105.9%	—	100.0%
当期純利益(△:損失) Net income(Δ:loss)	3,052	3,850	3,850	797	126.1%	—	100.0%
設備投資額(有形・無形) Capital expenditures	2,954	5,125	5,125	2,170	173.5%	—	100.0%
減価償却費(有形・無形) Depreciation and Amortization	2,968	3,000	2,900	△ 68	97.7%	△ 100	96.7%

*平成26年3月期の実績において、「その他」の一部を「その他酒類」と「海外日本食材卸」にそれぞれ組替えております。
（平成27年3月期の区分に合わせております。）

③ タカラバイオグループ :Takara Bio Group

（百万円 :Millions of Yen）

	平成26年3月期 FY2014	平成27年3月期 FY2015_Apr. 1, 2014 - Mar. 31, 2015		対前期 Change from FY2014		対5/8予想 Change from forecast announced May 2014	
	実績(a) Actual (a)	5/8予想(b) Forecast announced May 2014 (b)	11/5予想(c) Forecast announced Nov. 2014 (c)	増減(c-a) Change (c-a)	比(c/a) % (c/a)	増減(c-b) Change (c-b)	比(c/b) % (c/b)
研究用試薬 Research reagents	15,761	16,693	17,044	1,283	108.1%	351	102.1%
理化学機器 Scientific instruments	2,686	2,678	2,352	△ 333	87.6%	△ 325	87.8%
受託・その他ファイン Contracted service and other	3,215	3,381	3,354	139	104.3%	△ 26	99.2%
バイオ産業支援　計 Bioindustry	21,663	22,752	22,752	1,089	105.0%	—	100.0%
遺伝子医療 Gene Therapy	—	—	—	—	—	—	—
医食品バイオ AgriBio	2,242	2,447	2,447	205	109.1%	—	100.0%
売上高 Net sales	23,905	25,200	25,200	1,294	105.4%	—	100.0%
売上原価 Cost of sales	11,331	11,738	11,612	280	102.5%	△ 126	98.9%
売上総利益 Gross profit	12,574	13,461	13,588	1,013	108.1%	126	100.9%
運送費、保管料 Transportation and storage	537	549	606	69	113.0%	57	110.4%
広告宣伝費 Advertising	121	133	117	△ 3	96.7%	△ 16	88.0%
販売促進費 Sales promotion	985	890	855	△ 129	86.8%	△ 35	96.0%
研究開発費 Research and development	3,026	3,646	3,511	485	116.0%	△ 134	96.3%
管理費、その他 Other, net	5,949	6,241	6,495	546	109.2%	254	104.1%
販売費及び一般管理費 SG&A expenses	10,619	11,461	11,587	967	109.1%	125	101.1%
バイオ産業支援 Bioindustry	4,770	5,140	4,945	174	103.7%	△ 195	96.2%
遺伝子医療 Gene Therapy	△ 913	△ 1,434	△ 1,271	△ 357	—	163	—
医食品バイオ AgriBio	△ 285	△ 168	△ 158	127	—	10	—
共通 Eliminations/Corporate	△ 1,617	△ 1,536	△ 1,514	102	—	22	—
営業利益(△:損失) Operating income(Δ:loss)	1,954	2,000	2,000	46	102.4%	—	100.0%
営業外収益 Non-operating income	372	308	421	48	113.1%	112	136.6%
営業外費用 Non-operating expenses	86	58	42	△ 44	48.5%	△ 16	72.0%
経常利益(△:損失) Ordinary income(Δ:loss)	2,240	2,250	2,380	139	106.2%	129	105.8%
特別利益 Extraordinary income	0	—	—	△ 0	—	—	—
特別損失 Extraordinary loss	55	45	49	△ 5	89.4%	3	107.7%
税金等調整前当期純利益(△:損失) Income(Δ:loss) before income taxes	2,185	2,204	2,330	145	106.6%	126	105.7%
法人税、住民税及び事業税 Current income taxes	756	711	846	120	116.6%	135	119.0%
法人税等調整額 Deferred income taxes	△ 30						
少数株主損益調整前当期純利益(△:損失) Income(Δ:loss) before minority interests	1,458	1,493	1,483	24	101.7%	△ 9	99.4%
少数株主利益(△:損失) Minority interests in net income(Δ:loss)	△ 11	12	3	14	—	△ 9	26.1%
当期純利益(△:損失) Net income(Δ:loss)	1,470	1,480	1,480	10	100.7%	—	100.0%
設備投資額(有形・無形) Capital expenditures	5,538	4,444	4,444	△ 1,093	80.3%	—	100.0%
減価償却費(有形・無形) Depreciation and Amortization	1,157	1,325	1,351	194	116.8%	26	102.0%

*平成26年3月期の実績は、平成26年4月の組織改正後の新しい事業セグメントで算出しています。
（平成27年3月期の区分に合わせております。）